Arcus Biosciences Inc (RCUS)
15.38
+0.15
(+0.98%)
USD |
NYSE |
May 01, 13:22
Arcus Biosciences Shareholders Equity (Quarterly): 462.00M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 462.00M |
| September 30, 2023 | 520.00M |
| June 30, 2023 | 566.00M |
| March 31, 2023 | 600.00M |
| December 31, 2022 | 657.00M |
| September 30, 2022 | 698.70M |
| June 30, 2022 | 747.39M |
| March 31, 2022 | 796.58M |
| December 31, 2021 | 842.00M |
| September 30, 2021 | 542.61M |
| June 30, 2021 | 604.56M |
| March 31, 2021 | 664.79M |
| December 31, 2020 | 502.30M |
| Date | Value |
|---|---|
| September 30, 2020 | 544.42M |
| June 30, 2020 | 428.71M |
| March 31, 2020 | 140.64M |
| December 31, 2019 | 163.84M |
| September 30, 2019 | 177.23M |
| June 30, 2019 | 196.65M |
| March 31, 2019 | 221.57M |
| December 31, 2018 | 234.94M |
| September 30, 2018 | 245.12M |
| June 30, 2018 | 254.57M |
| March 31, 2018 | 266.59M |
| December 31, 2017 | 153.87M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
140.64M
Minimum
Mar 2020
842.00M
Maximum
Dec 2021
518.71M
Average
544.42M
Median
Sep 2020
Shareholders Equity (Quarterly) Benchmarks
| Gilead Sciences Inc | 17.46B |
| Catalyst Pharmaceuticals Inc | 387.88M |
| Integra Lifesciences Holdings Corp | 1.588B |
| Palatin Technologies Inc | -11.38M |
| Petros Pharmaceuticals Inc | 12.48M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.095B |
| Total Liabilities (Quarterly) | 633.00M |
| Current Ratio | 4.516 |